PARIS, Dec. 18, 2018 /PRNewswire/ -- Sanofi today
announced that it will be transferring the listing of its American
Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to
The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018, after market close. Sanofi's
ADSs are expected to begin trading as a Nasdaq-listed security at
market open on January 2, 2019, and
will continue to be listed under the ticker symbol "SNY." This
transition will not impact the company's primary listing on
Euronext (EURONEXT: SAN).
"This partnership with Nasdaq is a natural transition for
Sanofi as it provides greater cost-efficiencies as well as access
to a broad-based portfolio of investor relations tools to enhance
both market insights and our interaction with the financial
community," said Jean-Baptiste
Chasseloup de Chatillon, Executive Vice President, Chief
Financial Officer, Sanofi. "I want to thank the NYSE which was
our listing partner in the U.S. for many years."
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Media Relations
Contact
|
Investor Relations
Contact
|
Ashleigh
Koss
|
George
Grofik
|
Tel.: (908)
981-8745
|
Tel.: +33 (0)1 53 77
45 45
|
Ashleigh.Koss@sanofi.com
|
ir@sanofi.com
|
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, expectations for the transfer of our American
Depositary Shares (ADS) listing and the stock exchange on which our
ADSs will be listed, as well as those risks and uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or
statements
View original
content:http://www.prnewswire.com/news-releases/sanofi-to-transfer-us-stock-exchange-listing-to-nasdaq-300768401.html
SOURCE Sanofi